IGC Pharma (IGC) Retained Earnings (2011 - 2026)
IGC Pharma (IGC) reported Retained Earnings of -$127.3 million for Q1 2026, down 3541.08% year-over-year from $3.7 million in Q1 2025, and down 2132.8% quarter-over-quarter from -$5.7 million in Q4 2025.
IGC Pharma (IGC) Retained Earnings (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has 16 years of Retained Earnings data on file, last reported at -$127.3 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$127.3 million, down 3541.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$127.3 million (down 3541.08% YoY), and the FY2026 annual result was -$127.3 million, down 3541.08% from the prior year.
- Retained Earnings retreated to -$127.3 million in Q1 2026 per IGC's latest filing, from -$5.7 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$3.0 million in Q1 2022 and troughed at -$127.3 million in Q1 2026.
- A 5-year average of -$61.3 million and a median of -$91.9 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings surged 96.32% in 2023, then slumped 3541.08% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$3.4 million in 2022, then plunged by 3129.74% to -$110.8 million in 2023, then decreased by 7.95% to -$119.6 million in 2024, then soared by 95.23% to -$5.7 million in 2025, then tumbled by 2132.8% to -$127.3 million in 2026.
- Business Quant data shows IGC's Retained Earnings at -$127.3 million in Q1 2026, -$5.7 million in Q4 2025, and -$122.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -838.07 Mn |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | -127.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.29 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -122.83 Mn |
| Jun 30, 2025 | -122.34 Mn |
| Mar 31, 2025 | -3.50 Mn |
| Dec 31, 2024 | -119.59 Mn |
| Sep 30, 2024 | -117.76 Mn |
| Jun 30, 2024 | -3.43 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Dec 31, 2023 | -110.78 Mn |
| Sep 30, 2023 | -105.19 Mn |
| Jun 30, 2023 | -3.38 Mn |
| Mar 31, 2023 | -3.39 Mn |
| Dec 31, 2022 | -3.43 Mn |
| Sep 30, 2022 | -94.39 Mn |
| Jun 30, 2022 | -91.94 Mn |
| Mar 31, 2022 | -2.97 Mn |
| Dec 31, 2021 | -82.66 Mn |
| Sep 30, 2021 | -80.28 Mn |
| Jun 30, 2021 | -2.86 Mn |